Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Last Updated: Tuesday, November 18, 2025

Researchers report on the outcomes of 12 patients who received intrathecal chemotherapy for the treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) between 2017 and 2023. The data suggest that early administration of intrathecal chemotherapy is feasible and is highly effective in the management of ICANS; however, larger studies are needed to validate these findings.

Blood

Frontiers in Immunology

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

Blood

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Transplantation and Cellular Therapy

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

CAR T-Cell Therapy Resource Center

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Frontiers in Immunology

CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights

The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

Blood

Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity

Transplantation and Cellular Therapy

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets